I think is is way to early for a takeover at a reasonable share price that the shareholders would accept.
I am thinking that if the FDA has had visibility of the PMS Phase 2 results and they have similar efficacy as the pre-clinical mouse studies, then I am wondering if the FDA may have suggested a fast path for NNZ-2591 to get to PMS patients asap / quicker than planned. I am hoping this will be discussed on Monday as they results are announced.
Ann: Trading Halt, page-261
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.40 |
Change
-0.460(2.32%) |
Mkt cap ! $2.489B | |||
| Open | High | Low | Value | Volume |
| $19.70 | $19.77 | $19.28 | $8.793M | 451.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 214 | $19.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.41 | 95 | 8 |
View Market Depth
| Last trade - 15.34pm 30/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |